Evidence map›Paper›PMID 31075884›Full record

ReviewToxics2019

Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.

Michael A Malfatti, Bruce A Buchholz, Heather A Enright, Benjamin J Stewart, Ted J Ognibene, A Daniel McCartt, Gabriela G Loots, Maike Zimmermann, Tiffany M Scharadin, George D Cimino and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Identification and Quantitation ofMethods and protocols · 2025
    Article
  2. Separation of Lipoproteins for Quantitative Analysis ofInternational journal of molecular sciences · 2024
    Article
  3. HPLC-Parallel accelerator and molecular mass spectrometry analysis ofJournal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Michael A MalfattiBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. malfatti1@llnl.gov.
Bruce A BuchholzCenter for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. buchholz2@llnl.gov.ORCID 0000-0002-9531-551X
Heather A EnrightBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. enright3@llnl.gov.
Benjamin J StewartBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. stewart66@llnl.gov.
Ted J OgnibeneCenter for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. ognibene1@llnl.gov.
A Daniel McCarttCenter for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. mccartt1@llnl.gov.
Gabriela G LootsBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. loots1@llnl.gov.
Maike ZimmermannDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA. mzimmermann@ucdavis.edu.
Tiffany M ScharadinDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA. tscharadin@ucdavis.edu.
George D CiminoAccelerated Medical Diagnostics Incorporated, Berkeley, CA 94708, USA. george_cimino@comcast.net.
Brian A JonasDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA. bajonas@ucdavis.edu.
Chong-Xian PanDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA. cxpan@ucdavis.edu.
Graham BenchCenter for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. bench1@llnl.gov.
Paul T HendersonDepartment of Internal Medicine, Division of Hematology and Oncology and UC Davis Comprehensive Cancer Center, University of California Davis Medical School, Sacramento, CA 95817, USA. phenderson@ucdavis.edu.
Kenneth W TurteltaubBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA. turteltaub2@llnl.gov.
Lawrence Livermore National Laboratory · USAccelerated Medical Diagnostics (United States) · USUniversity of California Davis Medical Center · US

Funding

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)P41GM103483 · NIGMS · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI TURTELTAUB, KENNETH W. · 2012 to 2019
$12.0M
American Cancer Society IRG-95-125-16NIGMS NIH HHS P41 GM103483NIH HHS CA093373NIH HHS CA138464NIH HHS GM103483NIH HHS HHSN261201000133CNIH HHS HHSN261201200048CU.S. Department of Energy LDRD 08-LW-100
6 · The paper itself

Abstract

This review summarizes recent developments in radiocarbon tracer technology and applications. Technologies covered include accelerator mass spectrometry (AMS), including conversion of samples to graphite, and rapid combustion to carbon dioxide to enable direct liquid sample analysis, coupling to HPLC for real-time AMS analysis, and combined molecular mass spectrometry and AMS for analyte identification and quantitation. Laser-based alternatives, such as cavity ring down spectrometry, are emerging to enable lower cost, higher throughput measurements of biological samples. Applications covered include radiocarbon dating, use of environmental atomic bomb pulse radiocarbon content for cell and protein age determination and turnover studies, and carbon source identification. Low dose toxicology applications reviewed include studies of naphthalene-DNA adduct formation, benzo[a]pyrene pharmacokinetics in humans, and triclocarban exposure and risk assessment. Cancer-related studies covered include the use of radiocarbon-labeled cells for better defining mechanisms of metastasis and the use of drug-DNA adducts as predictive biomarkers of response to chemotherapy.

Indexed as

accelerator mass spectrometrybenzo[a]pyrenebiomarkerscavity ring down spectrophotometrycell turnoverDNA adductsmetastasisnaphthaleneradiocarbontriclocarban

Identifiers

PMID31075884
PMCPMC6631948
OpenAlexW2944252253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.